Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 324

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 324
---
 $6.5 million for the three months ended June 30, 2025, from $3.1 million for the three months ended June 30, 2024. The increase in general and administrative expenses was primarily due to:

•$2.3 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the size of our workforce; and

•$1.0 million increase in fees related to the increased use of consultants and professional service organizations.

Interest Income

Interest income increased by $1.1 million to $3.7 million for the three months ended June 30, 2025, from $2.6 million for the three months ended June 30, 2024, primarily driven by an increased investment in debt securities due to the proceeds received from the initial public offering and the amortization of discounts on our investment activity.

Other Income

Other income was $0.2 million for the three months ended June 30, 2025, and 2024, due to sublease income in connection with our subleasing agreement.

Comparison of the Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations (in thousands):

Six Months Ended June 30,Change20252024Operating expenses:Research and development$29,051 $18,453 $10,598 General and administrative12,514 5,986 6,528 Total operating expenses41,565 24,439 17,126 Loss from operations(41,565)(24,439)(17,126)Other income:Interest income6,667 3,698 2,969 Other income348 342 6 Total other income:7,015 4,040 2,975 Net loss$(34,550)$(20,399)$(14,151)

21

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Six Months Ended June 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$16,931 $7,773 $9,158 Complementary modulator programs2,281 4,135 (1,854)Unallocated research and development expenses:Personnel-related (including stock-based compensation)6,764 4,182 2,582 Other R&D related costs1,917 1,105 812 Facility